Drugs / rThrombin
rThrombin
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00371215 | Aug 2006 → Jun 2007 | — | ZymoGenetics | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00491608 | Jun 2007 → Jul 2008 | — | ZymoGenetics | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT00859547 | Mar 2009 → Jan 2010 | — | ZymoGenetics | Completed | No outcome recorded |
| Phase 4 | NCT00813904 | Jan 2009 → Jul 2010 | — | ZymoGenetics | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rThrombin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00813904 ↗ |
| Known as | recombinant human thrombin | “The immunogenicity and safety of recombinant human thrombin (rThrombin) were evaluated in this phase 3b, open-label, single-group, multisite study of 209 adult vascular and...” PMID 19651065 ↗ May 20092“A Phase 2 Study of Recombinant Human Thrombin (rThrombin) Administered Using a Spray Applicator in Subjects Undergoing Autologous Skin Grafting Following Burn or Traumatic Skin Injury” NCT00371215 ↗ “Previous studies of recombinant human thrombin (rThrombin) enrolled adult and adolescent patients.” PMID 22008340 ↗ Oct 2011 |
| Known as | recombinant thrombin | “The objective of this study is to assess the safety and immunogenicity of recombinant thrombin (rThrombin) administered as an aid to hemostasis during burn wound excision and...” NCT00859547 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human thrombin” NCT00371215 ↗ |
| Route | Topical | “treated with topical spray rThrombin at the skin graft recipient site” NCT00371215 ↗ |